Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

Phase 2positiveTEV-408Positive

AI Analysis

Summary

Teva's TEV-408 achieved its primary endpoint in a Phase IIa clinical trial for celiac disease treatment. The positive data advance the candidate toward further development.

Clinical Trial Data

Phase

IIa

Primary Endpoint

Met

Outcome Details

Hit key Phase IIa endpoint

Importance:7/10

Sentiment:

0.70

Phase 2 DataCeliac DiseaseEndpoint Achievement

Related Companies

$TEVJF

Read the original article

Published by yahoo_finance on September 2, 2026 2:02 PM

Read Original